Switching from blonanserin tablets to blonanserin transdermal patches improves tardive dyskinesia: A case report

Abstract

Tardive dyskinesia (TD) is a common side effect of antipsychotics, and it remains a persistent and challenging problem. The blonanserin transdermal patch, developed in Japan and launched in September 2019, is the first antipsychotic transdermal treatment. Here, we describe a patient with schizophrenia who exhibited markedly improved orofacial dyskinesia after switching from blonanserin tablets to blonanserin transdermal patches. We speculate that the patch formulation might have led to more stable plasma blonanserin levels, thus reducing the side effects. Specifically, the patch formulation might have contributed to stable plasma levels via the continuous and direct absorption of blonanserin through the skin.

Severe behavioral and psychological symptoms of dementia successfully treated at home with a blonanserin transdermal patch: A case report

“… 10 Extrapyramidal syndromes are reportedly decreased by switching from the blonanserin oral tablet to the blonanserin patch. 21 , 22 These characteristics of the blonanserin patch would be favorable for in‐home treatment because fewer side effects are expected.…”

“…Moreover, blonanserin also possesses a low risk of excessive sedation because of its low affinity for H1 and histaminergic receptors 10 . Extrapyramidal syndromes are reportedly decreased by switching from the blonanserin oral tablet to the blonanserin patch 21,22 . These characteristics of the blonanserin patch would be favorable for in‐home treatment because fewer side effects are expected.…”